Jae Lee, DO
Internal Medicine · Centennial, CONPI 1114918588
Payments from drug & device makers
Across 340 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$830
- Amgen$810
- Pfizer$580
- Boehringer Ingelheim$240
- Johnson & Johnson$174
- plus $1K from 32 others
What the payments were for
- Food & beverage$5,297100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $1,216 |
| AstraZeneca | 34 | $830 |
| Amgen(2 entities) | 67 | $810 |
| Pfizer | 43 | $580 |
| Boehringer Ingelheim | 16 | $240 |
| Johnson & Johnson(2 entities) | 9 | $174 |
| Novo Nordisk | 9 | $143 |
| Abbott | 1 | $142 |
| Sumitomo Pharma America, Inc. | 5 | $108 |
| Hikma Pharmaceuticals USA | 5 | $85 |
| Exact Sciences | 4 | $68 |
| Gilead | 4 | $66 |
| Lilly USA, LLC | 4 | $64 |
| Merck | 5 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Ironwood Pharmaceuticals, Inc | 3 | $55 |
| Scilex Pharmaceuticals Inc. | 2 | $47 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Sunovion Pharmaceuticals Inc. | 3 | $37 |
| Bayer | 2 | $35 |
| GSK | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Aimmune Therapeutics, Inc. | 2 | $28 |
| Astellas Pharma US Inc | 1 | $28 |
| Ardelyx, Inc. | 1 | $26 |
| Vertex | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Tonix Medicines, Inc. | 1 | $23 |
| VBI Vaccine (delaware) Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,303 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 155 | $233,083 |
| TradjentaLinagliptin | 84 | $108,619 |
| EliquisApixaban | 78 | $96,488 |
| JanuviaSitagliptin Phosphate | 76 | $96,359 |
| CreonLipase/Protease/Amylase | 47 | $81,170 |
| LinzessLinaclotide | 89 | $72,390 |
| MounjaroTirzepatide | 51 | $60,605 |
| MyrbetriqMirabegron | 53 | $51,184 |
| XareltoRivaroxaban | 31 | $45,690 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $38,004 |
| ProliaDenosumab | 20 | $35,854 |
| TrulicityDulaglutide | 33 | $35,205 |
| OzempicSemaglutide | 26 | $27,450 |
| FarxigaDapagliflozin Propanediol | 22 | $26,467 |
| InvokanaCanagliflozin | 25 | $24,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $240 | $341,702239 claims |
| AbbVieCreon, Linzess | $1,216 | $153,560136 claims |
| MerckJanuvia, Janumet, Janumet Xr, Belsomra, Dulera | $61 | $145,765136 claims |
| PfizerEliquis | $580 | $96,48878 claims |
| Lilly USA, LLCMounjaro, Trulicity | $64 | $95,81084 claims |
| Johnson & JohnsonXarelto, Invokana | $174 | $70,07856 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $830 | $52,77263 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $51,18453 claims |
| GSKTrelegy Ellipta | $32 | $38,00439 claims |
| AmgenProlia | $810 | $35,85420 claims |
| Novo NordiskOzempic | $143 | $27,45026 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $108 | $14,03018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Centennial
- Joel ShebowichCentennial$32K
- Jill SchofieldCentennial$10K
- Stanton ElziWheat Ridge$9.2M
- Jason HenryDenver$7.3M
- Kenneth CohenLakewood$4.5M
- Luke WebbColorado Springs$2.1M
- Alexis LealAurora$2M
- Mauricio WaintrubAurora$1.3M
- Steven BrodieColorado Springs$883K
- Monica GrafalsAvon$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.